Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer.
Hayashi N, Iwamoto T, Gonzalez-Angulo AM, Ferrer-Lozano J, Lluch A, Niikura N, Bartholomeusz C, Nakamura S, Hortobagyi GN, Ueno NT.
Hayashi N, et al.
Oncologist. 2011;16(7):956-65. doi: 10.1634/theoncologist.2010-0409. Epub 2011 Jun 28.
Oncologist. 2011.
PMID: 21712485
Free PMC article.